Latest Industry Insights

Dr. Madhuri Hegde discusses Revvity's role in the Generation Study, an ambitious initiative that will sequence the genomes of 100,000 newborns.

James Connelly discusses the importance of third-party verification and how recent funding will help accelerate the development of Impact Laboratories' digital sustainability tools.

At the BioTrinity 2025 conference, Technology Networks spoke with Dr. Pedro Correa de Sampaio, co-founder and CEO of Neobe, who are utilizing synthetic biology to engineer bacteria capable of breaking down the barriers within tumors.

A new pan-European network will integrate long-read sequencing into clinical practice, improving diagnosis of rare diseases and cancers.

In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and innovative manufacturing strategies are overcoming the key limitations of autologous CAR T-cell therapy.

In this opinion piece, Philipp Koellinger explores the changes required to level the playing field and accelerate both scientific and technological progress.

Dr. Aaron Wenger tells us about SPRQ chemistry, highlighting its unique benefits and role in expanding our understanding of rare diseases.

Hear from an early user of the neofleXTM MALDI-TOF instrument about how the technology adds new capabilities to MSI workflows.

Cell and gene therapies are revolutionizing medicine. Looking to 2025, advancements in allogeneic therapies, streamlined autologous processes and broader applications promise increased accessibility and innovation in treating complex diseases.

Technology Networks spoke with Dr. Mohamed Alameri to explore how population-wide genome initiatives are addressing gaps in genomic data representation and advancing precision medicine in areas such as rare diseases and cancer.